Lovell Stephanie 4
4 · TransMedics Group, Inc. · Filed Nov 23, 2022
Insider Transaction Report
Form 4
Lovell Stephanie
Director
Transactions
- Sale
Common Stock
2022-11-23$59.50/sh−5,657$336,592→ 0 total - Exercise/Conversion
Common Stock
2022-11-22$26.26/sh+1,100$28,886→ 1,100 total - Sale
Common Stock
2022-11-22$58.04/sh−1,100$63,844→ 0 total - Exercise/Conversion
Common Stock
2022-11-23$47.82/sh+5,657$270,518→ 5,657 total - Exercise/Conversion
Stock Option (Right to Buy)
2022-11-23−5,657→ 8,543 totalExercise: $47.82Exp: 2031-03-22→ Common Stock (5,657 underlying) - Sale
Common Stock
2022-11-22$57.97/sh−3,800$220,286→ 0 total - Exercise/Conversion
Stock Option (Right to Buy)
2022-11-22−3,800→ 14,200 totalExercise: $47.82Exp: 2031-03-22→ Common Stock (3,800 underlying) - Exercise/Conversion
Common Stock
2022-11-22$47.82/sh+3,800$181,716→ 3,800 total - Exercise/Conversion
Stock Option (Right to Buy)
2022-11-22−1,100→ 1,150 totalExercise: $26.26Exp: 2031-05-27→ Common Stock (1,100 underlying)
Footnotes (1)
- [F1]The option vested as to one-third of the shares subject to the option on March 22, 2022 and vests in equal monthly installments as to the remainder of the shares for two years thereafter.